Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome (MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2D), and high blood pressure, which are responsible for reduced life expectancy and poor adherence. Importantly, there is clear evidence that early metabolic disturbances can precede weight gain, even if the latter still remains the hallmark of AAPs use. In fact, AAPs interfere profoundly with glucose and lipid homeostasis acting mostly on hypothalamus, liver, pancreatic β-cells, adipose tissue, and skeletal muscle. Their actions on hypothalamic centers via dopamine, serotonin, acetylcholine, and histamine receptors affect neuropeptides and 5′AMP-activated protein kinase (AMPK) activity, thus producing a supraphysiological sympathetic outflow augmenting levels of glucagon and hepatic glucose production. In addition, altered insulin secretion, dyslipidemia, fat deposition in the liver and adipose tissues, and insulin resistance become aggravating factors for MetS. In clinical practice, among AAPs, olanzapine and clozapine are associated with the highest risk of MetS, whereas quetiapine, risperidone, asenapine and amisulpride cause moderate alterations. The new AAPs such as ziprasidone, lurasidone and the partial agonist aripiprazole seem more tolerable on the metabolic profile. However, these aspects must be considered together with the differences among AAPs in terms of their efficacy, where clozapine still remains the most effective. Intriguingly, there seems to be a correlation between AAP’s higher clinical efficacy and increase risk of metabolic alterations. Finally, a multidisciplinary approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a first-line strategy to avoid the MetS. In addition, pharmacological treatments are discussed as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 3×
“Several reviews and meta-analysis that systematically compared AAPs with TAPs in terms of efficacy and side effects found data supporting AAPs superiority for several aspects, but with an increased risk of developing MetS [8,107].”
BackgroundMethodResultHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Insulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191 · cited 3×
“Some studies have illustrated that an excess of FFAs induces insulin receptor inactivation and degradation, including disruption of IRS1 [100,101].”
BackgroundPillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Regulation of glucose metabolism from a liver-centric perspective
Han, H.-S., Kang, G., Kim, J. S., Choi, B. H., & Koo, S.-H. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.122 · Cited by 835
Life expectancy among persons with schizophrenia or bipolar affective disorder
Laursen, T. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.008 · Cited by 508 · cited 1×
“morbidity and mortality compared to the general population, where cardiovascular problems are the main cause of this decease and the estimated life expectancy drops down by 10–20 years [3].”
BackgroundGlucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 1×
“In addition, metformin seems to have cytoprotective properties by stimulating proliferation of pancreatic β-cells and reducing cellular apoptosis [152].”
BackgroundStephenne, X., Foretz, M., Taleux, N., van der Zon, G. C., Sokal, E., Hue, L., Viollet, B., & Guigas, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2311-5 · Cited by 287 · cited 1×
“In fact, when prolonged treatment with olanzapine results in an increase in hypothalamic phosphorylation of AMPK, metformin reduces AMPK activity with consequences in the food intake and glucose homeostasis [151].”
BackgroundLarsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Curtis, J., Watkins, A., Rosenbaum, S., Teasdale, S., Kalucy, M., Samaras, K., & Ward, P. B. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12230 · Cited by 227
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195 · cited 1×
“with compensatory stimulation of the β-cells [63,89].”
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152 · cited 1×
“Seven out of nine studies showed a significant association between olanzapine and T2D, whereas three out of four studies found the same evidence for clozapine [118,119].”
ResultEstimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182983ffa · Cited by 125 · cited 1×
“These analyses have also found that the relationship between Cp and D2 receptor occupancy is fit by a hyperbolic saturation curve, where risperidone and olanzapine, at higher concentration, may exceed 80% of receptor occupancy [174].”
BackgroundA Potential Mechanism Underlying Atypical Antipsychotics-Induced Lipid Disturbances
Cai, H. L., Tan, Q. Y., Jiang, P., Dang, R. L., Xue, Y., Tang, M. M., Xu, P., Deng, Y., Li, H. D., & Yao, J. K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.161 · Cited by 86
Antipsychotics and glucose metabolism: how brain and body collide
Kowalchuk, C., Castellani, L. N., Chintoh, A., Remington, G., Giacca, A., & Hahn, M. K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00164.2018 · Cited by 85 · cited 2×
“In fact, 25% of patients develop hyperglycemia without gaining weight and this metabolic alteration can happen in the early period of the treatments and precede weight gain [9].”
BackgroundNicol, G. E., Yingling, M. D., Flavin, K. S., Schweiger, J. A., Patterson, B. W., Schechtman, K. B., & Newcomer, J. W. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1088 · Cited by 83
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77 · cited 1×
“In addition, the possible role of GIP as a pro-inflammatory factor in adipose tissue has also been considered [51].”
BackgroundGlucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Jönsson, C., Castor Batista, A. P., Kjølhede, P., & Strålfors, P. (2019) · Biochemical Journal · doi:10.1042/bcj20190594 · Cited by 34 · cited 15×
“The other FFA receptor GPR119 expressed in β-cells is associated with a Gs protein, and it increases insulin secretion by rising the intracellular levels of cAMP [24].”
BackgroundInfluential
Cited by
The role of adipokines in health and disease
Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023) · Biomedicines · doi:10.3390/biomedicines11051290 · Cited by 463
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53
Dopamine-mediated autocrine inhibition of insulin secretion
Ferrero, E., Masini, M., Carli, M., Moscato, S., Beffy, P., Vaglini, F., Mattii, L., Corti, A., Scarselli, M., Novelli, M., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112294 · Cited by 4
“The drugs most frequently associated with metabolic adverse reactions are the atypical antipsychotic drugs (Carli et al., 2021a), which are distinguished from first generation drugs on the basis of a lower frequency of motor side effects (Aringhieri et al., 2018; Kowalchuk et al., 2019).”
Self-citation
Metadata
- Authors
- Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-03-08
- Volume
- 14
- Issue
- 3
- Pages
- 238
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3133688715
- Cited by
- 250
- References
- 23
- FWCI
- 21.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.